Not finding it? Sign in to also search OpenAlex live.
-
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study
Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, +4 more
4citations -
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Anna Gayà, Morag Griffin, Bing Han, Austin Gladston Kulasekararaj, Jaroslaw Pawel Maciejewski, +11 more
0citations -
Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort
Hilde T. van der Galiën, Pim G. N. J. Mutsaers, Margot Jak, Marjolein van der Poel, Marije T. Nijk, Kees Meijer, +13 more
1citations -
FC096: Von Willebrand Factor: A Central Regulator of Arteriovenous Fistula Maturation2022 Nephrology Dialysis Transplantation conference-abstract Health Professions Central Venous Catheters and Hemodialysis Open access
Suzanne L. Laboyrie, Margreet R. de Vries, Laisel Martinez, Roberto I. Vázquez-Padrón, Joris I. Rotmans
0citations
10 results